Assessment of dose contribution to pelvic lymph nodes in patients undergoing brachytherapy for carcinoma cervix
DOI:
https://doi.org/10.3126/ajms.v15i12.69957Keywords:
Brachytherapy; Mean absolute dose; Pelvic lymph nodes; Carcinoma cervixAbstract
Background: The inclusion of pelvic lymph node (PLN) metastasis in the FIGO staging system has impacted disease classification and patient survival. Brachytherapy is a key component in managing carcinoma cervix; however, the dose contribution of brachytherapy to PLNs remains unclear.
Aims and Objectives: This study aims to quantify the dose contribution of high-dose rate (HDR) brachytherapy to individual pelvic nodal groups.
Materials and Methods: We included 40 biopsy-proven carcinoma cervix patients, stages IIA to IVA. All patients underwent external beam radiotherapy (EBRT) with concurrent cisplatin chemotherapy, followed by HDR brachytherapy, either intracavitary brachytherapy (ICBT) or interstitial brachytherapy (ISBT). A total dose of 21 Gy in 3 fractions (7 Gy per fraction) was prescribed to the high-risk clinical target volume.
Results: For ICBT, the mean absolute doses received by the external iliac, internal iliac, and obturator groups were 0.56 Gy, 1.02 Gy, and 1.22 Gy, corresponding to EQD2 (α/β=10) values of 0.49 Gy, 0.93 Gy, and 1.14 Gy, respectively. In the ISBT group, the mean absolute doses were 0.49 Gy, 0.86 Gy, and 1.11 Gy, with corresponding EQD2s of 0.43 Gy, 0.85 Gy, and 1.02 Gy.
Conclusion: PLNs received significant dose contributions from HDR brachytherapy in cervical cancer patients, providing valuable reference data for determining the EBRT boost dose in cases of enlarged PLNs.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
